👤 Zuping Zhou

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
1335
Articles
847
Name variants
Also published as: Aiping Zhou, Aiwu Zhou, Alicia Y Zhou, An Zhou, Ang Zhou, Anna Y Zhou, Annan Zhou, Ao Zhou, Aojia Zhou, Aoshuang Zhou, Apei Zhou, Baiwan Zhou, Bao-Sen Zhou, Baohua Zhou, Baojuan Zhou, Baosen Zhou, Beixian Zhou, Beiyi Zhou, Bin Zhou, Bincheng Zhou, Bing Zhou, Bingbing Zhou, Binghai Zhou, Bingqian Zhou, Bingqing Zhou, Bingying Zhou, Binhua P Zhou, Binhua Zhou, Birong Zhou, Bo Zhou, Bo-Ya Zhou, Bo-Yang Zhou, Bubo Zhou, C Zhou, C-J Zhou, Can Zhou, Carl Zhou, Cefan Zhou, Chang Zhou, Chang-Yin Zhou, Changfan Zhou, Changhua Zhou, Changqi Zhou, Changrui Zhou, Changshuai Zhou, Changwen Zhou, Chao Zhou, Chen-Hui Zhou, Chen-Liang Zhou, Chenchen Zhou, Cheng Zhou, Chengji J Zhou, Chenhao Zhou, Chenkang Zhou, Chenqi Zhou, Chenxia Zhou, Chong Zhou, Chong-zhi Zhou, Chongwei Zhou, ChuHuan Zhou, Chuan-Min Zhou, Chuan-Wei Zhou, Chuan-Xiang Zhou, Chuan-chuan Zhou, Chuanen Zhou, Chuanman Zhou, Chuhao Zhou, Chun-Man Zhou, Chun-Ni Zhou, Chunlei Zhou, Chunlin Zhou, Chunni Zhou, Chunxian Zhou, Chunxiu Zhou, Chunyu Zhou, Chunzhuang Zhou, Chuyu Zhou, Cui Zhou, Cuiqi Zhou, Da Zhou, Daijun Zhou, Daizhan Zhou, Dan Zhou, Danmei Zhou, Danxia Zhou, Dao Zhou, David Zhou, Dawei Zhou, Daxin Zhou, Degang Zhou, Dejun Zhou, Dezheng Zhou, Dingan Zhou, Dingzi Zhou, Dong-Sheng Zhou, Dongdong Zhou, Donger Zhou, Dongfang Zhou, Donghai Zhou, Dongjie Zhou, Dongmei Zhou, Dongsheng Zhou, Duanfang Zhou, Duo-Qi Zhou, Duoqi Zhou, Enchen Zhou, Ershun Zhou, F Zhou, Fachen Zhou, Fan Zhou, Fanfan Zhou, Fang Zhou, Fangfang Zhou, Fangli Zhou, Fangting Zhou, Fei Zhou, Feixue Zhou, Feiye Zhou, Feng Zhou, Feng-Quan Zhou, Fenghua Zhou, Fengrui Zhou, Fengyun Zhou, Fenling Zhou, Fu-Ling Zhou, Fude Zhou, Fuling Zhou, Fusheng Zhou, Fuxiang Zhou, Fuyou Zhou, G Zhou, Gang Zhou, Grace Guoying Zhou, Guangji Zhou, Guangjun Zhou, Guangming Zhou, Guangqian Zhou, Guangzhou Zhou, Gui-Feng Zhou, Guifeng Zhou, Guiju Zhou, Guili Zhou, Guiting Zhou, Guo Zhou, Guo-Kun Zhou, Guohong Zhou, Guohua Zhou, Guoli Zhou, Guoyu Zhou, Guyue Zhou, H Zhou, Haibo Zhou, Haihong Zhou, Haihua Zhou, Haijing Zhou, Haimei Zhou, Hairui Zhou, Haixu Zhou, Haiyan Zhou, Haiyuan Zhou, Haiyue Zhou, Han Zhou, Hang Zhou, Hang-Yu Zhou, Hangfan Zhou, Hanshen Zhou, Hanxiao Zhou, Hao Zhou, Hao-Min Zhou, Haobo Zhou, Haonan Zhou, Haoxiong Zhou, Haoyuan Zhou, He Zhou, Helen Zhou, HengCui Zhou, Heying Zhou, Hong Zhou, Hong-Yu Zhou, Honghong Zhou, Hongji Zhou, Honglei Zhou, Hongli Zhou, Hongmei Zhou, Hongmin Zhou, Hongshan Zhou, Hongwei Zhou, Hongwen Zhou, Hongyan Zhou, Hou-De Zhou, Hu Zhou, Hua Ying Zhou, Hua Zhou, Hua-Bang Zhou, Huadong Zhou, Huaijun Zhou, Huamao Zhou, Huan Zhou, Huangao Zhou, Huanjin Zhou, Huanyu Zhou, Huaqiang Zhou, Hui Zhou, Hui-Fen Zhou, Huifang Zhou, Huifen Zhou, Huihui Zhou, Huimin Zhou, Huinian Zhou, Huiqiang Zhou, Huiwen Zhou, J Zhou, Jeff Xiwu Zhou, Ji Zhou, Ji-Chao Zhou, Ji-Ying Zhou, Jia Zhou, Jia-Guo Zhou, Jia-le Zhou, Jiahe Zhou, Jiahua Zhou, Jiajie Zhou, Jiale Zhou, Jiamei Zhou, Jian Zhou, Jian-Peng Zhou, JianJiang Zhou, Jianan Zhou, Jianfen Zhou, Jianfeng Zhou, Jiang-Ning Zhou, Jiangfei Zhou, Jianghao Zhou, Jianghong Zhou, Jianghui Zhou, Jianglin Zhou, Jiangqiao Zhou, Jianguo Zhou, Jianhua Zhou, Jianling Zhou, Jianmin Zhou, Jianqing Zhou, Jianshe Zhou, Jianwei Zhou, Jianying Zhou, Jianzhong Zhou, Jiaqi Zhou, Jiaru Zhou, Jiawang Zhou, Jiawei Zhou, Jiawen Zhou, Jiaxi Zhou, Jiaxiang Zhou, Jiaxin Zhou, Jiayan Zhou, Jiayi Zhou, Jiayin Zhou, Jie Zhou, Jiechao Zhou, Jiefu Zhou, Jieru Zhou, Jieyan Zhou, Jieyu Zhou, Jin Zhou, Jin-Ting Zhou, Jin-Yong Zhou, JinQiu Zhou, Jing Zhou, Jing-Wei Zhou, Jing-Xuan Zhou, Jingbo Zhou, Jingjie Zhou, Jingjing Zhou, Jingjun Zhou, Jingpei Zhou, Jingqi Zhou, Jingwen Zhou, Jingyi Zhou, Jingyu Zhou, Jingyuan Zhou, Jinting Zhou, Jinyi Zhou, Jiuyao Zhou, Jiyong Zhou, John Zhou, Ju Zhou, Juan Zhou, Juanjuan Zhou, Jue-Yu Zhou, Julian Q Zhou, Jun Zhou, Jun-Min Zhou, Jun-Ying Zhou, Jun-Yu Zhou, Jundong Zhou, Junfeng Zhou, Jungu Zhou, Junguo Zhou, Junhe Zhou, Junjie Zhou, Junjun Zhou, Junting Zhou, Junya Zhou, Junyu Zhou, Justin Zhou, Juying Zhou, Kaicheng Zhou, Kaixia Zhou, Kaixin Zhou, Kaiyu Zhou, Kan Zhou, Ke Zhou, Kecheng Zhou, Kefu Zhou, Kejin Zhou, Kexun Zhou, Lamei Zhou, Lan Zhou, Lang Zhou, Lanlan Zhou, Lanping Zhou, Lanqi Zhou, Laura Y Zhou, Le Zhou, Lei Zhou, Lei-Lei Zhou, Li Zhou, Li-Jun Zhou, Liang Zhou, Liangdong Zhou, Liangfu Zhou, Liangrui Zhou, Liangxue Zhou, Liangyu Zhou, Libin Zhou, Libing Zhou, Libo Zhou, Liche Zhou, Lihong Zhou, Lihuan Zhou, Lijun Zhou, Lili Zhou, Limin Zhou, Lin Zhou, Lina Zhou, Linda Zhou, Ling Zhou, Ling-Yun Zhou, Linglin Zhou, Lingshan Zhou, Lingyi Zhou, Lingyun Zhou, Linjun Zhou, Linnan Zhou, Linran Zhou, Lipeng Zhou, Liqun Zhou, Lisha Zhou, Lisheng Zhou, Liting Zhou, Liufang Zhou, Liuqing Zhou, Liuxin Zhou, Lixin Zhou, Liye Zhou, Long Zhou, Lu Zhou, Lufang Zhou, Luling Zhou, Luming Zhou, Lunni Zhou, Luo-Qi Zhou, Luting Zhou, M M Zhou, Maoge Zhou, Maotian Zhou, Mei Zhou, Meijing Zhou, Meilan Zhou, Meiqi Zhou, Meirong Zhou, Meiyi Zhou, Meng-Tao Zhou, Meng-Yao Zhou, Menghua Zhou, Mengkai Zhou, Menglong Zhou, Mengna Zhou, Mengqi Zhou, Mengqian Zhou, Mengze Zhou, Mi Zhou, Miao Zhou, Min Zhou, Ming Zhou, Ming-Ju Zhou, Ming-Ming Zhou, Ming-Sheng Zhou, Mingfeng Zhou, Minglei Zhou, Minglian Zhou, Mingmei Zhou, Mingming Zhou, Mingping Zhou, Mingqi Zhou, Minling Zhou, Minyi Zhou, Molin Zhou, Na Zhou, Nan Zhou, Neng Zhou, Ni Zhou, Nian Zhou, Nianwei Zhou, Ning Zhou, Ningying Zhou, Niuniu Zhou, P Zhou, Pei Zhou, Peng Zhou, Penghui Zhou, Pijun Zhou, Ping Zhou, Ping-Kun Zhou, Pingkun Zhou, Pingxi Zhou, Pingxin Zhou, Puhui Zhou, Q Zhou, Qi Zhou, Qian Zhou, Qiang Zhou, Qianxin Zhou, Qiao Zhou, Qiaoxia Zhou, Qidong Zhou, Qin Zhou, Qin-Yi Zhou, Qing Zhou, Qing-Bing Zhou, Qing-Qing Zhou, Qingbing Zhou, Qingbo Zhou, Qingchun Zhou, Qinghua Zhou, Qingniao Zhou, Qingnv Zhou, Qingping Zhou, Qingtong Zhou, Qingxin Zhou, Qingyu Zhou, Qiong Zhou, Qiu-Min Zhou, Qiu-Zhi Zhou, Qiyang Zhou, Qiyin Zhou, Quan Zhou, Qun Zhou, R B Zhou, Ranran Zhou, Raorao Zhou, Ren Zhou, Rong Zhou, Rong-Yan Zhou, Rongbin Zhou, Rongjia Zhou, Rongxian Zhou, Rongxuan Zhou, Rongyan Zhou, Rouxi Zhou, Ru Zhou, Ruchen Zhou, Rui Zhou, Ruihai Zhou, Ruijun Zhou, Ruimei Zhou, Ruisi Zhou, Runjin Zhou, Ruyi Zhou, S A Zhou, S R Zhou, S Zhou, S-G Zhou, Sa Zhou, Sanshun Zhou, Sha Zhou, Shanshan Zhou, Shao-Lai Zhou, Shaobo Zhou, Shaoli Zhou, Shaolong Zhou, Sheng-Nan Zhou, Shenghua Zhou, Shenghui Zhou, Shengwen Zhou, Shengyang Zhou, Shengyi Zhou, Shenping Zhou, Shiao Zhou, Shibo Zhou, Shiyi Zhou, Shu Zhou, Shuaishuai Zhou, Shuaiyang Zhou, Shuang Zhou, Shuling Zhou, Shumin Zhou, Shun Zhou, Shuo Zhou, Si Zhou, Si-Qi Zhou, Siquan Zhou, Sirui Zhou, Song Zhou, Songhui Zhou, Sufang Zhou, Sumei Zhou, Suqing Zhou, Suzhen Zhou, T Zhou, Tai-Cheng Zhou, Taimei Zhou, Tao Zhou, Tengxiao Zhou, Ti Zhou, Tian-Li Zhou, Tianhua Zhou, Tianqiong Zhou, Tianrong Zhou, Tianxing Zhou, Tianyan Zhou, Tianyu Zhou, Tiger Zhou, Ting Zhou, Tingting Zhou, Tong Zhou, Vincent Zhou, W Zhou, Wan-hao Zhou, Wang Zhou, Wei Zhou, Weihua Zhou, Weihui Zhou, Weijiao Zhou, Weijie Zhou, Weiming Zhou, Weinan Zhou, Weiqiang Zhou, Weishang Zhou, Weiwei Zhou, Weiying Zhou, Wen Zhou, Wen-Chao Zhou, Wen-Hao Zhou, Wen-Jie Zhou, Wen-Quan Zhou, Wenbin Zhou, Wenbo Zhou, Wenchao Zhou, Wenfang Zhou, Wenhao Zhou, Wenjie Zhou, Wenjing Zhou, Wenke Zhou, Wenqing Zhou, Wenrong Zhou, Wenwen Zhou, Wenxing Zhou, Wenyu Zhou, Wenzong Zhou, Wesley Zhou, Wu Zhou, Wuduo Zhou, Wuyuan Zhou, X F Zhou, X Q Zhou, X-T Zhou, Xi Zhou, Xia Zhou, Xia-Bo Zhou, Xiang Zhou, Xiangda Zhou, Xiangdong Zhou, Xianghai Zhou, Xiangrong Zhou, Xianguo Zhou, Xiangyu Zhou, Xiangyuan Zhou, Xianhu Zhou, Xianhua Zhou, Xianhui Zhou, Xianjing Zhou, Xianliang Zhou, Xianxiao Zhou, Xiao Zhou, Xiao-Hai Zhou, Xiao-Ting Zhou, Xiao-Yu Zhou, Xiaobo Zhou, Xiaochuan Zhou, Xiaochun Zhou, Xiaofeng Zhou, Xiaohai Zhou, Xiaohan Zhou, Xiaohui Zhou, Xiaojing Zhou, Xiaolei Zhou, Xiaoli Zhou, Xiaolin Zhou, Xiaoling Zhou, Xiaomao Zhou, Xiaoming Zhou, Xiaonan Zhou, Xiaopu Zhou, Xiaoqian Zhou, Xiaorong Zhou, Xiaorui Zhou, Xiaoshu Zhou, Xiaosu Zhou, Xiaotong Zhou, Xiaowen Zhou, Xiaoxi Zhou, Xiaoxia Zhou, Xiaoxue Zhou, Xiaoyan Zhou, Xiaoye Zhou, Xiaoying Zhou, Xiaozhong Zhou, Xidan Zhou, Xin Tong Zhou, Xin Zhou, Xin-Rong Zhou, Xin-Yu Zhou, Xin-Yue Zhou, Xingtao Zhou, Xinhong Zhou, Xinhua Zhou, Xinming Zhou, Xinyan Zhou, Xinyao Zhou, Xinyi Zhou, Xinyue Zhou, Xinzhi Zhou, Xiqiu Zhou, Xiu-Ping Zhou, Xiuhong Zhou, Xiuling Zhou, Xiuping Zhou, Xiuteng Zhou, Xiyi Zhou, Xu Yu Zhou, Xu Zhou, Xu-Hua Zhou, Xuan Zhou, Xuanchen Zhou, Xuchang Zhou, Xue Dong Zhou, Xue Zhou, Xue-Yan Zhou, Xuedong Zhou, Xuefeng Zhou, Xuejie Zhou, Xueli Zhou, Xueliang Zhou, Xueqin Zhou, Xueqing Zhou, Xueshi Zhou, Xujie Zhou, Xun Zhou, Xuyu Zhou, Y J Zhou, Y Zhou, Y-L Zhou, Yachuan Zhou, Yadi Zhou, Yahui Zhou, Yajun Zhou, Yan Zhou, Yan-Yan Zhou, Yanbing Zhou, Yandong Zhou, Yanfen Zhou, Yang Zhou, Yangbo Zhou, Yangying Zhou, Yanhao Zhou, Yanheng Zhou, Yanhua Zhou, Yanjiao Zhou, Yanjie Zhou, Yanli Zhou, Yanling Zhou, Yanmeng Zhou, Yanqiu Zhou, Yanrong Zhou, Yanyi Zhou, Yao Zhou, Yaping Zhou, Yaqi Zhou, Yating Zhou, Yeyun Zhou, Yi Zhou, Yi-Hui Zhou, Yi-Jiang Zhou, Yichao Zhou, Yidan Zhou, Yifa Zhou, Yifeng Zhou, Yinan Zhou, Ying Zhou, Ying-Hui Zhou, Yinghui Zhou, Yingjie Zhou, Yingmin Zhou, Yingshi Zhou, Yiqing Zhou, Yitian Zhou, Yong Zhou, Yong-Gang Zhou, Yong-Hui Zhou, Yong-an Zhou, Yongbing Zhou, Yongcan Zhou, Yonghua Zhou, Yongjian Zhou, Yongqiang Zhou, Yongtao Zhou, Yongxin Zhou, Yongzhi Zhou, You Lang Zhou, You Zhou, You-Li Zhou, Youping Zhou, Yu Zhou, Yu-Bao Zhou, Yu-Ning Zhou, Yu-Qi Zhou, Yuan Zhou, Yuanyuan Zhou, Yubin Zhou, Yudong Zhou, Yue Zhou, Yueping Zhou, Yuetao Zhou, Yufei Zhou, Yuhan Zhou, Yuhuan Zhou, Yujia Zhou, Yujie Zhou, Yun Zhou, Yun-Fei Zhou, Yun-Tao Zhou, Yunfang Zhou, Yunfeng Zhou, Yunhui Zhou, Yunqian Zhou, Yunxia Zhou, Yunxiang Zhou, Yunyun Zhou, Yunzhen Zhou, Yuqi Zhou, Yuqiao Zhou, Yuqing Zhou, Yuqiu Zhou, Yushan Zhou, Yuting Zhou, Yutong Zhou, Yuxin Zhou, Yuzhi Zhou, Zechen Zhou, Zefeng Zhou, Zenghui Zhou, Zengyuan Zhou, Zengzi Zhou, Zewei Zhou, Zhan Zhou, Zhaokai Zhou, Zhechong Zhou, Zhen Zhou, Zheng Zhou, Zheng-Jun Zhou, Zheng-Yang Zhou, Zhengyang Zhou, Zhengzhong Zhou, Zhenhua Zhou, Zhenlei Zhou, Zhenying Zhou, Zhenyu Zhou, Zheyi Zhou, Zhi Dong Zhou, Zhi Zhou, Zhi-Dong Zhou, Zhi-Gang Zhou, Zhi-Hang Zhou, Zhi-Jiao Zhou, Zhi-Xiang Zhou, Zhi-Yong Zhou, Zhibo Zhou, Zhicheng Zhou, Zhifeng Zhou, Zhiguang Zhou, Zhihang Zhou, Zhihao Zhou, Zhiheng Zhou, Zhihui Zhou, Zhijiao Zhou, Zhijun Zhou, Zhimin Zhou, Zhipeng Zhou, Zhiqin Zhou, Zhiqun Zhou, Zhiwei Zhou, Zhixiang Zhou, Zhiyi Zhou, Zhiyong Zhou, Zhiyu Zhou, Zhongbo Zhou, Zhongjiang Zhou, Zhongkai Zhou, Zhongqiu Zhou, Zhongtao Zhou, Zhongxing Zhou, Zhongyin Zhou, Zhou Zhou, Zhu Zhou, Zhuoming Zhou, Zi-Yang Zhou, Zi-Yi Zhou, Zihan Zhou, Zihao Zhou, Zihua Zhou, Zijun Zhou, Zili Zhou, Ziliang Zhou, Zilin Zhou, Zilong Zhou, Zipeng Zhou, Ziqing Zhou, Ziwei Zhou, Ziyan Zhou, Ziyue Zhou, Ziyun Zhou, Zongkai Zhou, Zunchun Zhou, Zuomin Zhou, Zuoqiong Zhou,
articles
Fenling Zhou, Lu Chen, Peng Lu +3 more · 2023 · BMC cancer · BioMed Central · added 2026-04-24
Diffuse large B-cell lymphoma (DLBCL) is one of the most aggressive malignant tumors. Chromobox (CBX) family plays the role of oncogenes in various malignancies. The transcriptional and protein levels Show more
Diffuse large B-cell lymphoma (DLBCL) is one of the most aggressive malignant tumors. Chromobox (CBX) family plays the role of oncogenes in various malignancies. The transcriptional and protein levels of CBX family were confirmed by GEPIA, Oncomine, CCLE, and HPA database. Screening of co-expressed genes and gene function enrichment analysis were performed by GeneMANIA and DAVID 6.8. The prognostic value, immune cell infiltration and drug sensitivity analysis of CBX family in DLBCL were performed by Genomicscape, TIMER2.0, and GSCALite database. Confirmatory Tests of CBX family protein expression in DLBCL were performed by immunohistochemistry. The mRNA and protein expressions of CBX1/2/3/5/6 were higher in DLBCL tissues than control groups. Enrichment analysis showed that the functions of CBX family were mainly related to chromatin remodeling, methylation-dependent protein binding, and VEGF signaling pathway. The high mRNA expressions of CBX2/3/5/6 were identified to be associated with short overall survival (OS) in DLBCL patients. Multivariate COX regression indicated that CBX3 was independent prognostic marker. Immune infiltration analysis revealed that the mRNA expressions of CBX family (especially CBX1, CBX5, and CBX6) in DLBCL were significantly correlated with the infiltration of most immune cells (including B cells, CD8 + T cells, CD4 + T cells, neutrophils, monocytes, macrophages, and Treg cells). Meanwhile, there was a strong correlation between the expression levels of CBX1/5/6 and surface markers of immune cells, such as the widely studied PVR-like protein receptor/ligand and PDL-1 immune checkpoint. Notably, our study found that DLBCL cells with CBX1 over-expression were resistant to the common anti-tumor drugs, but CBX2/5 had two polarities. Finally, we confirmed the higher expressions of CBX1/2/3/5/6 in DLBCL tissues compared with control groups by immunohistochemistry. We provided a detailed analysis of the relationship between the CBX family and the prognosis of DLBCL. Distinguished from other studies, We found that high mRNA expressions of CBX2/3/5/6 were associated with poor prognosis in DLBCL patients, and Multivariate COX regression indicated that CBX3 was independent prognostic marker. Besides, our study also found an association between the CBX family and anti-tumour drug resistance, and provided a relationship between CBX family expression and immune cell infiltration. Show less
📄 PDF DOI: 10.1186/s12885-023-11108-6
CBX1
Rongli Fan, Die Hu, Maiqiu Wang +3 more · 2023 · Frontiers in genetics · Frontiers · added 2026-04-24
📄 PDF DOI: 10.3389/fgene.2023.1153518
CBX1
Xuan Meng, Runfu Cao, Xiaoqiang Liu +8 more · 2023 · Oncology letters · added 2026-04-24
Bladder urothelial carcinoma (BLCA) accounts for 95% of all cases of bladder cancer worldwide, with a high incidence and poor prognosis. Chromobox (CBX) proteins play a key role in numerous malignant Show more
Bladder urothelial carcinoma (BLCA) accounts for 95% of all cases of bladder cancer worldwide, with a high incidence and poor prognosis. Chromobox (CBX) proteins play a key role in numerous malignant tumors; however, the role of CBX in BLCA remains unknown. Herein, the present study found that, compared with in normal bladder tissues, the expression levels of CBX1, CBX2, CBX3, CBX4 and CBX8 were markedly increased in BLCA tissues, as determined by Tumor Immune Estimation Resource, UALCAN and ONCOMINE analyses, whereas CBX6 and CBX7 were decreased in BLCA tissues. Furthermore, evident hypomethylation in the promoters of CBX1, and CBX2, as well as significant hypermethylation in the promoters of CBX5, CBX6 and CBX7, was detected in BLCA tissues compared with in normal bladder tissues. The expression of CBX1, CBX2 and CBX7 was involved in the prognosis of patients with BLCA. Low CBX7 expression was strongly associated with poorer overall survival in patients with BLCA, whereas high CBX1 and CBX2 expression was associated with poorer progression-free survival. Besides, significant associations were determined between the expression of CBXs and immune cell infiltration, including dendritic cells, neutrophils, macrophages, CD4 Show less
📄 PDF DOI: 10.3892/ol.2023.13758
CBX1
Junchen Leng, Xiaotong Wei, Xinyi Jin +12 more · 2023 · The Plant cell · Oxford University Press · added 2026-04-24
Arbuscular mycorrhizal (AM) symbiosis is a widespread, ancient mutualistic association between plants and fungi, and facilitates nutrient uptake into plants. Cell surface receptor-like kinases (RLKs) Show more
Arbuscular mycorrhizal (AM) symbiosis is a widespread, ancient mutualistic association between plants and fungi, and facilitates nutrient uptake into plants. Cell surface receptor-like kinases (RLKs) and receptor-like cytoplasmic kinases (RLCKs) play pivotal roles in transmembrane signaling, while few RLCKs are known to function in AM symbiosis. Here, we show that 27 out of 40 AM-induced kinases (AMKs) are transcriptionally upregulated by key AM transcription factors in Lotus japonicus. Nine AMKs are only conserved in AM-host lineages, among which the SPARK-RLK-encoding gene KINASE3 (KIN3) and the RLCK paralogues AMK8 and AMK24 are required for AM symbiosis. KIN3 expression is directly regulated by the AP2 transcription factor CTTC MOTIF-BINDING TRANSCRIPTION FACTOR1 (CBX1), which regulates the reciprocal exchange of nutrients in AM symbiosis, via the AW-box motif in the KIN3 promoter. Loss of function mutations in KIN3, AMK8, or AMK24 result in reduced mycorrhizal colonization in L. japonicus. AMK8 and AMK24 physically interact with KIN3. KIN3 and AMK24 are active kinases and AMK24 directly phosphorylates KIN3 in vitro. Moreover, CRISPR-Cas9-mediated mutagenesis of OsRLCK171, the sole homolog of AMK8 and AMK24 in rice (Oryza sativa), leads to diminished mycorrhization with stunted arbuscules. Overall, our results reveal a crucial role of the CBX1-driven RLK/RLCK complex in the evolutionarily conserved signaling pathway enabling arbuscule formation. Show less
📄 PDF DOI: 10.1093/plcell/koad050
CBX1
Enchen Zhou, Xiaoke Ge, Hiroyuki Nakashima +14 more · 2023 · EMBO molecular medicine · added 2026-04-24
Liver X receptor (LXR) agonism has theoretical potential for treating NAFLD/NASH, but synthetic agonists induce hyperlipidemia in preclinical models. Desmosterol, which is converted by Δ24-dehydrochol Show more
Liver X receptor (LXR) agonism has theoretical potential for treating NAFLD/NASH, but synthetic agonists induce hyperlipidemia in preclinical models. Desmosterol, which is converted by Δ24-dehydrocholesterol reductase (DHCR24) into cholesterol, is a potent endogenous LXR agonist with anti-inflammatory properties. We aimed to investigate the effects of DHCR24 inhibition on NAFLD/NASH development. Here, by using APOE*3-Leiden. CETP mice, a well-established translational model that develops diet-induced human-like NAFLD/NASH characteristics, we report that SH42, a published DHCR24 inhibitor, markedly increases desmosterol levels in liver and plasma, reduces hepatic lipid content and the steatosis score, and decreases plasma fatty acid and cholesteryl ester concentrations. Flow cytometry showed that SH42 decreases liver inflammation by preventing Kupffer cell activation and monocyte infiltration. LXRα deficiency completely abolishes these beneficial effects of SH42. Together, the inhibition of DHCR24 by SH42 prevents diet-induced hepatic steatosis and inflammation in a strictly LXRα-dependent manner without causing hyperlipidemia. Finally, we also showed that SH42 treatment decreased liver collagen content and plasma alanine transaminase levels in an established NAFLD model. In conclusion, we anticipate that pharmacological DHCR24 inhibition may represent a novel therapeutic strategy for treatment of NAFLD/NASH. Show less
📄 PDF DOI: 10.15252/emmm.202216845
CETP
Zhuang Li, Enchen Zhou, Cong Liu +15 more · 2023 · JCI insight · added 2026-04-24
Short-chain fatty acids, including butyrate, have multiple metabolic benefits in individuals who are lean but not in individuals with metabolic syndrome, with the underlying mechanisms still being unc Show more
Short-chain fatty acids, including butyrate, have multiple metabolic benefits in individuals who are lean but not in individuals with metabolic syndrome, with the underlying mechanisms still being unclear. We aimed to investigate the role of gut microbiota in the induction of metabolic benefits of dietary butyrate. We performed antibiotic-induced microbiota depletion of the gut and fecal microbiota transplantation (FMT) in APOE*3-Leiden.CETP mice, a well-established translational model for developing human-like metabolic syndrome, and revealed that dietary butyrate reduced appetite and ameliorated high-fat diet-induced (HFD-induced) weight gain dependent on the presence of gut microbiota. FMT from butyrate-treated lean donor mice, but not butyrate-treated obese donor mice, into gut microbiota-depleted recipient mice reduced food intake, attenuated HFD-induced weight gain, and improved insulin resistance. 16S rRNA and metagenomic sequencing on cecal bacterial DNA of recipient mice implied that these effects were accompanied by the selective proliferation of Lachnospiraceae bacterium 28-4 in the gut as induced by butyrate. Collectively, our findings reveal a crucial role of gut microbiota in the beneficial metabolic effects of dietary butyrate as strongly associated with the abundance of Lachnospiraceae bacterium 28-4. Show less
📄 PDF DOI: 10.1172/jci.insight.166655
CETP
Cong Liu, Milena Schönke, Borah Spoorenberg +16 more · 2023 · eLife · added 2026-04-24
Analogues of the hepatokine fibroblast growth factor 21 (FGF21) are in clinical development for type 2 diabetes and nonalcoholic steatohepatitis (NASH) treatment. Although their glucose-lowering and i Show more
Analogues of the hepatokine fibroblast growth factor 21 (FGF21) are in clinical development for type 2 diabetes and nonalcoholic steatohepatitis (NASH) treatment. Although their glucose-lowering and insulin-sensitizing effects have been largely unraveled, the mechanisms by which they alleviate liver injury have only been scarcely addressed. Here, we aimed to unveil the mechanisms underlying the protective effects of FGF21 on NASH using APOE*3-Leiden.CETP mice, a well-established model for human-like metabolic diseases. Liver-specific FGF21 overexpression was achieved in mice, followed by administration of a high-fat high-cholesterol diet for 23 weeks. FGF21 prevented hepatic lipotoxicity, accompanied by activation of thermogenic tissues and attenuation of adipose tissue inflammation, improvement of hyperglycemia and hypertriglyceridemia, and upregulation of hepatic programs involved in fatty acid oxidation and cholesterol removal. Furthermore, FGF21 inhibited hepatic inflammation, as evidenced by reduced Kupffer cell (KC) activation, diminished monocyte infiltration, and lowered accumulation of monocyte-derived macrophages. Moreover, FGF21 decreased lipid- and scar-associated macrophages, which correlated with less hepatic fibrosis as demonstrated by reduced collagen accumulation. Collectively, hepatic FGF21 overexpression limits hepatic lipotoxicity, inflammation, and fibrogenesis. Mechanistically, FGF21 blocks hepatic lipid influx and accumulation through combined endocrine and autocrine signaling, respectively, which prevents KC activation and lowers the presence of lipid- and scar-associated macrophages to inhibit fibrogenesis. Show less
📄 PDF DOI: 10.7554/eLife.83075
CETP
Jin-Peng Gao, Wenjie Liang, Suyu Jiang +4 more · 2023 · The New phytologist · Blackwell Publishing · added 2026-04-24
no PDF DOI: 10.1111/nph.18759
CPS1
Sisi Zhang, Yue Hu, Zilong Wu +11 more · 2023 · International journal of radiation oncology, biology, physics · Elsevier · added 2026-04-24
Tumor radiation resistance is the main obstacle to effective radiation therapy for patients with hepatocellular carcinoma (HCC). We identified the role of urea cycle key enzyme carbamoyl phosphate syn Show more
Tumor radiation resistance is the main obstacle to effective radiation therapy for patients with hepatocellular carcinoma (HCC). We identified the role of urea cycle key enzyme carbamoyl phosphate synthetase 1 (CPS1) in radioresistance of HCC and explored its mechanism, aiming to provide a novel radiosensitization strategy for the CPS1-deficiency HCC subtype. The expression of CPS1 was measured by western blot and immunohistochemistry. Cell growth assay, EdU assay, cell apoptosis assay, cell cycle assay, clone formation assay, and subcutaneous tumor assay were performed to explore the relationship between CPS1 and radioresistance of HCC cells. Lipid metabonomic analysis was used for investigating the effects of CPS1 on lipid synthesis of HCC cells. RNA sequencing and coimmunoprecipitation assay were carried out to reveal the mechanism of CPS1 participating in the regulation of HCC radiation therapy resistance. Furthermore, 10074-G5, the specific inhibitor of c-Myc, was administered to HCC cells to investigate the role of c-Myc in CPS1-deficiency HCC cells. We found that urea cycle key enzyme CPS1 was frequently lower in human HCC samples and positively associated with the patient's prognosis. Functionally, the present study proved that CPS1 depletion could accelerate the development of HCC and induce radiation resistance of HCC in vitro and in vivo, and deficiency of CPS1 promoted the synthesis of some lipid molecules. Regarding the mechanism, we uncovered that inhibition of CPS1 upregulated CyclinA2 and CyclinD1 by stabilizing oncoprotein c-Myc at the posttranscriptional level and generated radioresistance of HCC cells. Moreover, inactivation of c-Myc using 10074-G5, a specific c-Myc inhibitor, could partially attenuate the proliferation and radioresistance induced by depletion of CPS1. Our results recapitulated that silencing CPS1 could promote HCC progression and radioresistance via c-Myc stability mediated by the ubiquitin-proteasome system, suggesting that targeting c-Myc in CPS1-deficiency HCC subtype may be a valuable radiosensitization strategy in the treatment of HCC. Show less
no PDF DOI: 10.1016/j.ijrobp.2022.11.022
CPS1
Xianyang Liu, Jiayu Meng, Xingyun Liao +13 more · 2023 · Cellular & molecular immunology · Nature · added 2026-04-24
Vogt-Koyanagi-Harada (VKH) disease is a leading cause of blindness in young and middle-aged people. However, the etiology of VKH disease remains unclear. Here, we performed the first trio-based whole- Show more
Vogt-Koyanagi-Harada (VKH) disease is a leading cause of blindness in young and middle-aged people. However, the etiology of VKH disease remains unclear. Here, we performed the first trio-based whole-exome sequencing study, which enrolled 25 VKH patients and 50 controls, followed by a study of 2081 VKH patients from a Han Chinese population to uncover detrimental mutations. A total of 15 de novo mutations in VKH patients were identified, with one of the most important being the membrane palmitoylated protein 2 (MPP2) p.K315N (MPP2-N315) mutation. The MPP2-N315 mutation was highly deleterious according to bioinformatic predictions. Additionally, this mutation appears rare, being absent from the 1000 Genome Project and Genome Aggregation Database, and it is highly conserved in 10 species, including humans and mice. Subsequent studies showed that pathological phenotypes and retinal vascular leakage were aggravated in MPP2-N315 mutation knock-in or MPP2-N315 adeno-associated virus-treated mice with experimental autoimmune uveitis (EAU). In vitro, we used clustered regularly interspaced short palindromic repeats (CRISPR‒Cas9) gene editing technology to delete intrinsic MPP2 before overexpressing wild-type MPP2 or MPP2-N315. Levels of cytokines, such as IL-1β, IL-17E, and vascular endothelial growth factor A, were increased, and barrier function was destroyed in the MPP2-N315 mutant ARPE19 cells. Mechanistically, the MPP2-N315 mutation had a stronger ability to directly bind to ANXA2 than MPP2-K315, as shown by LC‒MS/MS and Co-IP, and resulted in activation of the ERK3/IL-17E pathway. Overall, our results demonstrated that the MPP2-K315N mutation may increase susceptibility to VKH disease. Show less
📄 PDF DOI: 10.1038/s41423-023-01088-9
DLG2
Mingqian Xu, Jiarui Lin, Shuaibing Yang +7 more · 2023 · Journal of virology · added 2026-04-24
Epstein-Barr virus (EBV)-encoded miRNAs within the BamHI-A rightward transcript (BART) region are abundantly expressed in EBV-associated gastric cancer (EBVaGC), suggesting that they play roles in tum Show more
Epstein-Barr virus (EBV)-encoded miRNAs within the BamHI-A rightward transcript (BART) region are abundantly expressed in EBV-associated gastric cancer (EBVaGC), suggesting that they play roles in tumorigenesis. However, how these viral miRNAs contribute to the development of EBVaGC remains largely obscure. In this study, we found that EBV-encoded miR-BART11-3p targets 3' -UTR of dual-specificity phosphatase 6 (DUSP6) mRNA to upregulate ERK phosphorylation and downregulate JNK and p38 phosphorylation. By doing so, miR-BART11-3p promotes gastric cancer (GC) cell proliferation, migration, and invasion Show less
no PDF DOI: 10.1128/jvi.00881-23
DUSP6
Youran Chen, Yi Pan, Hanyu Gao +5 more · 2023 · Journal of cancer research and clinical oncology · Springer · added 2026-04-24
Glioblastoma (GBM) is one of the most common malignant brain tumors in adults and is characterized by high aggressiveness and rapid progression, poor treatment, high recurrence rate, and poor prognosi Show more
Glioblastoma (GBM) is one of the most common malignant brain tumors in adults and is characterized by high aggressiveness and rapid progression, poor treatment, high recurrence rate, and poor prognosis. Although super-enhancer (SE)-driven genes haven been recognized as prognostic markers for several cancers, whether it can be served as effective prognostic markers for patients with GBM has not been evaluated. We first combined histone modification data with transcriptome data to identify SE-driven genes associated with prognosis in patients with GBM. Second, we developed a SE-driven differentially expressed genes (SEDEGs) risk score prognostic model by univariate Cox analysis, KM survival analysis, multivariate Cox analysis and least absolute shrinkage and selection operator (LASSO) regression. Its reliability in predicting was verified by two external data sets. Third, through mutation analysis, immune infiltration, we explored the molecular mechanisms of prognostic genes. Next, Genomics of Drug Sensitivity in Cancer (GDSC) and the Connectivity Map (cMap) database were employed to assess different sensitivities to chemotherapeutic agents and small-molecule drug candidates between high- and low-risk patients. Finally, SEanalysis database was chosen to identify SE-driven transcription factors (TFs) regulating prognostic markers which will reveal a potential SE-driven transcriptional regulatory network. First, we developed a 11-gene risk score prognostic model (NCF2, MTHFS, DUSP6, G6PC3, HOXB2, EN2, DLEU1, LBH, ZEB1-AS1, LINC01265, and AGAP2-AS1) selected from 1,154 SEDEGs, which is not only an independent prognostic factor for patients, but also can effectively predict the survival rate of patients. The model can effectively predict 1-, 2- and 3-year survival of patients and was validated in external Chinese Glioma Genome Atlas (CGGA) and Gene Expression Omnibus (GEO) datasets. Second, the risk score was positively correlated with the infiltration of regulatory T cell, CD4 memory activated T cell, activated NK cell, neutrophil, resting mast cell, M0 macrophage, and memory B cell. Third, we found that high-risk patients showed higher sensitivity than low-risk patients to both 27 chemotherapeutic agents and 4 small-molecule drug candidates which might benefit further precision therapy for GBM patients. Finally, 13 potential SE-driven TFs imply how SE regulates GBM patient's prognosis. The SEDEG risk model not only helps to elucidate the impact of SEs on the course of GBM, but also provides a bright future for prognosis determination and choice of treatment for GBM patients. Show less
no PDF DOI: 10.1007/s00432-023-05121-2
DUSP6
Weiwei Zhang, Leping Liu, Xiangcheng Xiao +11 more · 2023 · Frontiers in immunology · Frontiers · added 2026-04-24
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the main cause of COVID-19, causing hundreds of millions of confirmed cases and more than 18.2 million deaths worldwide. Acute kidney in Show more
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the main cause of COVID-19, causing hundreds of millions of confirmed cases and more than 18.2 million deaths worldwide. Acute kidney injury (AKI) is a common complication of COVID-19 that leads to an increase in mortality, especially in intensive care unit (ICU) settings, and chronic kidney disease (CKD) is a high risk factor for COVID-19 and its related mortality. However, the underlying molecular mechanisms among AKI, CKD, and COVID-19 are unclear. Therefore, transcriptome analysis was performed to examine common pathways and molecular biomarkers for AKI, CKD, and COVID-19 in an attempt to understand the association of SARS-CoV-2 infection with AKI and CKD. Three RNA-seq datasets (GSE147507, GSE1563, and GSE66494) from the GEO database were used to detect differentially expressed genes (DEGs) for COVID-19 with AKI and CKD to search for shared pathways and candidate targets. A total of 17 common DEGs were confirmed, and their biological functions and signaling pathways were characterized by enrichment analysis. MAPK signaling, the structural pathway of interleukin 1 (IL-1), and the Toll-like receptor pathway appear to be involved in the occurrence of these diseases. Hub genes identified from the protein-protein interaction (PPI) network, including DUSP6, BHLHE40, RASGRP1, and TAB2, are potential therapeutic targets in COVID-19 with AKI and CKD. Common genes and pathways may play pathogenic roles in these three diseases mainly through the activation of immune inflammation. Networks of transcription factor (TF)-gene, miRNA-gene, and gene-disease interactions from the datasets were also constructed, and key gene regulators influencing the progression of these three diseases were further identified among the DEGs. Moreover, new drug targets were predicted based on these common DEGs, and molecular docking and molecular dynamics (MD) simulations were performed. Finally, a diagnostic model of COVID-19 was established based on these common DEGs. Taken together, the molecular and signaling pathways identified in this study may be related to the mechanisms by which SARS-CoV-2 infection affects renal function. These findings are significant for the effective treatment of COVID-19 in patients with kidney diseases. Show less
📄 PDF DOI: 10.3389/fimmu.2023.961642
DUSP6
Patrick Ernst, Seulhee Kim, Zengqiao Yang +2 more · 2023 · Frontiers in physiology · Frontiers · added 2026-04-24
📄 PDF DOI: 10.3389/fphys.2023.1257739
DYM
Lianqian Wu, Zefeng Zhou, Devavrat Sathe +5 more · 2023 · Nature chemistry · Nature · added 2026-04-24
The composition, sequence, length and type of glycosidic linkage of polysaccharides profoundly affect their biological and physical properties. However, investigation of the structure-function relatio Show more
The composition, sequence, length and type of glycosidic linkage of polysaccharides profoundly affect their biological and physical properties. However, investigation of the structure-function relationship of polysaccharides is hampered by difficulties in accessing well-defined polysaccharides in sufficient quantities. Here we report a chemical approach to precision polysaccharides with native glycosidic linkages via living cationic ring-opening polymerization of 1,6-anhydrosugars. We synthesized well-defined polysaccharides with tunable molecular weight, low dispersity and excellent regio- and stereo-selectivity using a boron trifluoride etherate catalyst and glycosyl fluoride initiators. Computational studies revealed that the reaction propagated through the monomer α-addition to the oxocarbenium and was controlled by the reversible deactivation of the propagating oxocarbenium to form the glycosyl fluoride dormant species. Our method afforded a facile and scalable pathway to multiple biologically relevant precision polysaccharides, including D-glucan, D-mannan and an unusual L-glucan. We demonstrated that catalytic depolymerization of precision polysaccharides efficiently regenerated monomers, suggesting their potential utility as a class of chemically recyclable materials with tailored thermal and mechanical properties. Show less
📄 PDF DOI: 10.1038/s41557-023-01193-2
DYM
Xiaoyan Sun, Jing Jiang, Gaofu Wang +7 more · 2023 · Animal bioscience · added 2026-04-24
This study aimed to investigate the significant single nucleotide polymorphisms (SNPs) and genes associated with nine reproduction and morphological traits in three breed populations of Chinese goats. Show more
This study aimed to investigate the significant single nucleotide polymorphisms (SNPs) and genes associated with nine reproduction and morphological traits in three breed populations of Chinese goats. The genome-wide association of nine reproduction and morphological traits (litter size, nipple number, wattle, skin color, coat color, black dorsal line, beard, beard length, and hind leg hair) were analyzed in three Chinese native goat breeds (n = 336) using an Illumina Goat SNP50 Beadchip. A total of 17 genome-wide or chromosome-wide significant SNPs associated with one reproduction trait (litter size) and six morphological traits (wattle, coat color, black dorsal line, beard, beard length, and hind leg hair) were identified in three Chinese native goat breeds, and the candidate genes were annotated. The significant SNPs and corresponding putative candidate genes for each trait are as follows: two SNPs located on chromosomes 6 (CSN3) and 24 (TCF4) for litter size trait; two SNPs located on chromosome 9 (KATNA1) and 1 (UBASH3A) for wattle trait; three SNPs located on chromosome 26 (SORCS3), 24 (DYM), and 20 (PDE4D) for coat color trait; two SNPs located on chromosome 18 (TCF25) and 15 (CLMP) for black dorsal line trait; four SNPs located on chromosome 8, 2 (PAX3), 5 (PIK3C2G), and 28 (PLA2G12B and OIT3) for beard trait; one SNP located on chromosome 18 (KCNG4) for beard length trait; three SNPs located on chromosome 17 (GLRB and GRIA2), 28 (PGBD5), and 4 for hind leg hair trait. In contrast, there were no SNPs identified for nipple number and skin color. The significant SNPs or genes identified in this study provided novel insights into the genetic mechanism underlying important reproduction and morphological traits of three local goat breeds in Southern China as well as further potential applications for breeding goats. Show less
📄 PDF DOI: 10.5713/ab.21.0577
DYM
Siyu Yuan, Shaoqi Tian, Chuang Meng +4 more · 2023 · Animals : an open access journal from MDPI · MDPI · added 2026-04-24
The Chinese indigenous Shiqi (SQ) pigeon and the imported White King (WK) pigeon are two meat-type pigeon breeds of economical and nutritional importance in China. They displayed significant differenc Show more
The Chinese indigenous Shiqi (SQ) pigeon and the imported White King (WK) pigeon are two meat-type pigeon breeds of economical and nutritional importance in China. They displayed significant differences in such meat quality traits as intramuscular fat (IMF) content and fatty acid (FA) compositions in the breast muscles. In this study, we aimed to screen candidate genes that could affect fat-related meat quality traits in meat-type pigeons. We investigated the polymorphic variations at the genomic level using double-digest restriction-associated DNA (ddRAD) sequencing in 12 squabs of SQ and WK pigeons that exhibited significant inter-breed differences in IMF content as well as FA and amino acid compositions in the breast muscles, and screened candidate genes influencing fat-related traits in squabs through gene ontology analysis and pathway analysis. By focusing on 6019 SNPs, which were located in genes with correct annotations and had the potential to induce changes in the encoded proteins, we identified 19 genes ( Show less
📄 PDF DOI: 10.3390/ani13203256
FADS1
Kaylia M Reynolds, Andrea R V R Horimoto, Bridget M Lin +14 more · 2023 · Genome medicine · BioMed Central · added 2026-04-24
Metabolic pathways are related to physiological functions and disease states and are influenced by genetic variation and environmental factors. Hispanics/Latino individuals have ancestry-derived genom Show more
Metabolic pathways are related to physiological functions and disease states and are influenced by genetic variation and environmental factors. Hispanics/Latino individuals have ancestry-derived genomic regions (local ancestry) from their recent admixture that have been less characterized for associations with metabolite abundance and disease risk. We performed admixture mapping of 640 circulating metabolites in 3887 Hispanic/Latino individuals from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Metabolites were quantified in fasting serum through non-targeted mass spectrometry (MS) analysis using ultra-performance liquid chromatography-MS/MS. Replication was performed in 1856 nonoverlapping HCHS/SOL participants with metabolomic data. By leveraging local ancestry, this study identified significant ancestry-enriched associations for 78 circulating metabolites at 484 independent regions, including 116 novel metabolite-genomic region associations that replicated in an independent sample. Among the main findings, we identified Native American enriched genomic regions at chromosomes 11 and 15, mapping to FADS1/FADS2 and LIPC, respectively, associated with reduced long-chain polyunsaturated fatty acid metabolites implicated in metabolic and inflammatory pathways. An African-derived genomic region at chromosome 2 was associated with N-acetylated amino acid metabolites. This region, mapped to ALMS1, is associated with chronic kidney disease, a disease that disproportionately burdens individuals of African descent. Our findings provide important insights into differences in metabolite quantities related to ancestry in admixed populations including metabolites related to regulation of lipid polyunsaturated fatty acids and N-acetylated amino acids, which may have implications for common diseases in populations. Show less
📄 PDF DOI: 10.1186/s13073-023-01209-z
FADS1
Jianxin Shi, Kouya Shiraishi, Jiyeon Choi +219 more · 2023 · Nature communications · Nature · added 2026-04-24
Jianxin Shi, Kouya Shiraishi, Jiyeon Choi, Keitaro Matsuo, Tzu-Yu Chen, Juncheng Dai, Rayjean J Hung, Kexin Chen, Xiao-Ou Shu, Young Tae Kim, Maria Teresa Landi, Dongxin Lin, Wei Zheng, Zhihua Yin, Baosen Zhou, Bao Song, Jiucun Wang, Wei Jie Seow, Lei SONG, I-Shou Chang, Wei Hu, Li-Hsin Chien, Qiuyin Cai, Yun-Chul Hong, Hee Nam Kim, Yi-Long Wu, Maria Pik Wong, Brian Douglas Richardson, Karen M Funderburk, Shilan Li, Tongwu Zhang, Charles Breeze, Zhaoming Wang, Batel Blechter, Bryan A Bassig, Jin Hee Kim, Demetrius Albanes, Jason Y Y Wong, Min-Ho Shin, Lap Ping Chung, Yang Yang, She-Juan An, Hong Zheng, Yasushi Yatabe, Xu-Chao Zhang, Young-Chul Kim, Neil E Caporaso, Jiang Chang, James Chung Man Ho, Michiaki Kubo, Yataro Daigo, Minsun Song, Yukihide Momozawa, Yoichiro Kamatani, Masashi Kobayashi, Kenichi Okubo, Takayuki Honda, Dean H Hosgood, Hideo Kunitoh, Harsh Patel, Shun-Ichi Watanabe, Yohei Miyagi, Haruhiko Nakayama, Shingo Matsumoto, Hidehito Horinouchi, Masahiro Tsuboi, Ryuji Hamamoto, Koichi Goto, Yuichiro Ohe, Atsushi Takahashi, Akiteru Goto, Yoshihiro Minamiya, Megumi Hara, Yuichiro Nishida, Kenji Takeuchi, Kenji Wakai, Koichi Matsuda, Yoshinori Murakami, Kimihiro Shimizu, Hiroyuki Suzuki, Motonobu Saito, Yoichi Ohtaki, Kazumi Tanaka, Tangchun Wu, Fusheng Wei, Hongji Dai, Mitchell J Machiela, Jian Su, Yeul Hong Kim, In-Jae Oh, Victor Ho Fun Lee, Gee-Chen Chang, Ying-Huang Tsai, Kuan-Yu Chen, Ming-Shyan Huang, Wu-Chou Su, Yuh-Min Chen, Adeline Seow, Jae Yong Park, Sun-Seog Kweon, Kun-Chieh Chen, Yu-Tang Gao, Biyun Qian, Chen Wu, Daru Lu, Jianjun Liu, Ann G Schwartz, Richard Houlston, Margaret R Spitz, Ivan P Gorlov, Xifeng Wu, Ping Yang, Stephen Lam, Adonina Tardon, Chu Chen, Stig E Bojesen, Mattias Johansson, Angela Risch, Heike Bickeböller, Bu-Tian Ji, H-Erich Wichmann, David C Christiani, Gadi Rennert, Susanne Arnold, Paul Brennan, James McKay, John K Field, Sanjay S Shete, Loic Le Marchand, Geoffrey Liu, Angeline Andrew, Lambertus A Kiemeney, Shan Zienolddiny-Narui, Kjell Grankvist, Mikael Johansson, Angela Cox, Fiona Taylor, Jian-Min Yuan, Philip Lazarus, Matthew B Schabath, Melinda C Aldrich, Hyo-Sung Jeon, Shih Sheng Jiang, Jae Sook Sung, Chung-Hsing Chen, Chin-Fu Hsiao, Yoo Jin Jung, Huan Guo, Zhibin Hu, Laurie Burdett, Meredith Yeager, Amy Hutchinson, Belynda Hicks, Jia Liu, Bin Zhu, Sonja I Berndt, Wei Wu, Junwen Wang, Yuqing Li, Jin Eun Choi, Kyong Hwa Park, Sook Whan Sung, Li Liu, Chang Hyun Kang, Wen-Chang Wang, Jun Xu, Peng Guan, Wen Tan, Chong-Jen Yu, Gong Yang, Alan Dart Loon Sihoe, Ying Chen, Yi Young Choi, Jun Suk Kim, Ho-Il Yoon, In Kyu Park, Ping Xu, Qincheng He, Chih-Liang Wang, Hsiao-Han Hung, Roel C H Vermeulen, Iona Cheng, Junjie Wu, Wei-Yen Lim, Fang-Yu Tsai, John K C Chan, Jihua Li, Hongyan Chen, Hsien-Chih Lin, Li Jin, Jie Liu, Norie Sawada, Taiki Yamaji, Kathleen Wyatt, Shengchao A Li, Hongxia Ma, Meng Zhu, Zhehai Wang, Sensen Cheng, Xuelian Li, Yangwu Ren, Ann Chao, Motoki Iwasaki, Junjie Zhu, Gening Jiang, Ke Fei, Guoping Wu, Chih-Yi Chen, Chien-Jen Chen, Pan-Chyr Yang, Jinming Yu, Victoria L Stevens, Joseph F Fraumeni, Nilanjan Chatterjee, Olga Y Gorlova, Chao Agnes Hsiung, Christopher I Amos, Hongbing Shen, Stephen J Chanock, Nathaniel Rothman, Takashi Kohno, Qing Lan Show less
Lung adenocarcinoma is the most common type of lung cancer. Known risk variants explain only a small fraction of lung adenocarcinoma heritability. Here, we conducted a two-stage genome-wide associatio Show more
Lung adenocarcinoma is the most common type of lung cancer. Known risk variants explain only a small fraction of lung adenocarcinoma heritability. Here, we conducted a two-stage genome-wide association study of lung adenocarcinoma of East Asian ancestry (21,658 cases and 150,676 controls; 54.5% never-smokers) and identified 12 novel susceptibility variants, bringing the total number to 28 at 25 independent loci. Transcriptome-wide association analyses together with colocalization studies using a Taiwanese lung expression quantitative trait loci dataset (n = 115) identified novel candidate genes, including FADS1 at 11q12 and ELF5 at 11p13. In a multi-ancestry meta-analysis of East Asian and European studies, four loci were identified at 2p11, 4q32, 16q23, and 18q12. At the same time, most of our findings in East Asian populations showed no evidence of association in European populations. In our studies drawn from East Asian populations, a polygenic risk score based on the 25 loci had a stronger association in never-smokers vs. individuals with a history of smoking (P Show less
📄 PDF DOI: 10.1038/s41467-023-38196-z
FADS1
Tingting Zhou, Ligang Cao, Yimei Du +5 more · 2023 · PeerJ · added 2026-04-24
Gypenosides (GP), extracted from the traditional Chinese herb
📄 PDF DOI: 10.7717/peerj.15225
FADS1
Chunjie Xu, Lei Gu, Lipeng Hu +10 more · 2023 · Nature communications · Nature · added 2026-04-24
Colonocyte metabolism shapes the microbiome. Metabolites are the main mediators of information exchange between intestine and microbial communities. Arachidonic acid (AA) is an essential polyunsaturat Show more
Colonocyte metabolism shapes the microbiome. Metabolites are the main mediators of information exchange between intestine and microbial communities. Arachidonic acid (AA) is an essential polyunsaturated fatty acid and its role in colorectal cancer (CRC) remains unexplored. In this study, we show that AA feeding promotes tumor growth in AOM/DSS and intestinal specific Apc Show less
📄 PDF DOI: 10.1038/s41467-023-37590-x
FADS1
Xiwen Zeng, Weimin Wang, Deyin Zhang +19 more · 2023 · Animal biotechnology · Taylor & Francis · added 2026-04-24
Growth traits are the economically important traits of sheep, and screening for genes related to growth and development is helpful for the genetic improvement of ovine growth traits. The fatty acid de Show more
Growth traits are the economically important traits of sheep, and screening for genes related to growth and development is helpful for the genetic improvement of ovine growth traits. The fatty acid desaturase 3 ( Show less
no PDF DOI: 10.1080/10495398.2023.2196313
FADS3
Ruyue Wang, Jinjing Zhong, Xiuyi Pan +7 more · 2023 · Journal of translational medicine · BioMed Central · added 2026-04-24
Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including ERK1/2, PI3K/AKT, PLCγ, and NF-κB. Aberrant expression o Show more
Fibroblast growth factor receptor 1 (FGFR1) is a core component of the FGFs/FGFR pathway that activates multiple signalling pathways, including ERK1/2, PI3K/AKT, PLCγ, and NF-κB. Aberrant expression of FGFR1 due to gene amplification, chromosome rearrangement, point mutation, and epigenetic deregulations, have been reported in various cancers. FGFR1 overexpression has also been reported in prostate cancer (PCa), but the underlining mechanisms are not clear. Here we report a novel circular RNA, circFGFR1 Show less
📄 PDF DOI: 10.1186/s12967-023-04718-y
FGFR1
Ting Deng, Le Zhang, Yehui Shi +10 more · 2023 · Investigational new drugs · Springer · added 2026-04-24
Pemigatinib is a selective fibroblast growth factor receptor (FGFR)1-3 inhibitor and has demonstrated acceptable tolerability and clinical activity in advanced solid tumors in Western population. This Show more
Pemigatinib is a selective fibroblast growth factor receptor (FGFR)1-3 inhibitor and has demonstrated acceptable tolerability and clinical activity in advanced solid tumors in Western population. This phase I trial evaluated pharmacokinetics/pharmacodynamics (PK/PD) characteristics, preliminary safety and efficacy of pemigatinib in Chinese patients with advanced, solid tumors. Patients with unresectable advanced or metastatic solid tumors bearing FGF/FGFR1-3 alterations received oral pemigatinib at 13.5 mg once daily (QD) on a 2-weeks-on/1-week-off schedule. The primary endpoint was PK/PD characteristics; secondary endpoints were safety and efficacy. Twelve patients were enrolled (median age: 61 years, 58.3% males). PK data demonstrated pemigatinib (13.5 mg QD) was rapidly absorbed with a geometric mean elimination half-life of 11.3 h. The geometric mean values of maximum serum concentration and area under the plasma concentration-time curve from 0 to 24 h at steady state were 215.1 nmol/L and 2636.9 h·nmol/L, respectively. The mean clearance adjusted by bioavailability at steady state was low (11.8 L/h), and the apparent oral volume of distribution was moderate (170.5 L). The PD marker, serum phosphate level, increased on days 8 and 15 of cycle 1 (mean: 2.25 mg/dL, CV% [percent coefficient of variation]: 31.3%) and decreased to baseline post 1 week off. Three (25.0%) patients experienced grade ≥ 3 treatment-emergent adverse events. Partial response was confirmed in one patient with FGFR1-mutant esophageal carcinoma and one with FGFR2-mutant cholagiocarcinoma. Pemigatinib had similar PK/PD characteristics to Western population and demonstrated an acceptable safety profile and potential anti-cancer benefit in Chinese patients with FGF/FGFR1-3 altered, advanced, solid tumor. (ClinicalTrials.gov: NCT04258527 [prospectively registered February 6, 2020]). Show less
📄 PDF DOI: 10.1007/s10637-023-01396-x
FGFR1
Na Zhao, Elena B Kabotyanski, Alexander B Saltzman +18 more · 2023 · The Journal of clinical investigation · added 2026-04-24
Protein synthesis is frequently dysregulated in cancer and selective inhibition of mRNA translation represents an attractive cancer therapy. Here, we show that therapeutically targeting the RNA helica Show more
Protein synthesis is frequently dysregulated in cancer and selective inhibition of mRNA translation represents an attractive cancer therapy. Here, we show that therapeutically targeting the RNA helicase eIF4A with zotatifin, the first-in-class eIF4A inhibitor, exerts pleiotropic effects on both tumor cells and the tumor immune microenvironment in a diverse cohort of syngeneic triple-negative breast cancer (TNBC) mouse models. Zotatifin not only suppresses tumor cell proliferation but also directly repolarizes macrophages toward an M1-like phenotype and inhibits neutrophil infiltration, which sensitizes tumors to immune checkpoint blockade. Mechanistic studies revealed that zotatifin reprograms the tumor translational landscape, inhibits the translation of Sox4 and Fgfr1, and induces an interferon (IFN) response uniformly across models. The induction of an IFN response is partially due to the inhibition of Sox4 translation by zotatifin. A similar induction of IFN-stimulated genes was observed in breast cancer patient biopsies following zotatifin treatment. Surprisingly, zotatifin significantly synergizes with carboplatin to trigger DNA damage and an even heightened IFN response, resulting in T cell-dependent tumor suppression. These studies identified a vulnerability of eIF4A in TNBC, potential pharmacodynamic biomarkers for zotatifin, and provide a rationale for new combination regimens consisting of zotatifin and chemotherapy or immunotherapy as treatments for TNBC. Show less
📄 PDF DOI: 10.1172/JCI172503
FGFR1
Siyue Yao, Xi Zhou, Min Gu +6 more · 2023 · Human genomics · BioMed Central · added 2026-04-24
Tooth agenesis is a common dental anomaly that can substantially affect both the ability to chew and the esthetic appearance of patients. This study aims to identify possible genetic factors that unde Show more
Tooth agenesis is a common dental anomaly that can substantially affect both the ability to chew and the esthetic appearance of patients. This study aims to identify possible genetic factors that underlie various forms of tooth agenesis and to investigate the possible molecular mechanisms through which human dental pulp stem cells may play a role in this condition. Using whole-exome sequencing of a Han Chinese family with non-syndromic tooth agenesis, a rare mutation in FGFR1 (NM₀₀₁₁₇₄₀₆₃.2: c.103G > A, p.Gly35Arg) was identified as causative and confirmed by Sanger sequencing. Via GeneMatcher, another family with a known variant (NM₀₀₁₁₇₄₀₆₃.2: c.1859G > A, p.Arg620Gln) was identified and diagnosed with tooth agenesis and a rare genetic disorder with considerable intrafamilial variability. Fgfr1 is enriched in the ectoderm during early embryonic development of mice and showed sustained low expression during normal embryonic development of Xenopus laevis frogs. Functional studies of the highly conserved missense variant c.103G > A showed deleterious effects. FGFR1 (c.103G > A) was overexpressed compared to wildtype and promoted proliferation while inhibiting apoptosis in HEK293 and human dental pulp stem cells. Moreover, the c.103G > A variant was found to suppress the epithelial-mesenchymal transition. The variant could downregulate ID4 expression and deactivate the TGF-beta signaling pathway by promoting the expression of SMAD6 and SMAD7. Our research broadens the mutation spectrum associated with tooth agenesis and enhances understanding of the underlying disease mechanisms of this condition. Show less
📄 PDF DOI: 10.1186/s40246-023-00539-8
FGFR1
Na Zhao, Elena B Kabotyanski, Alexander B Saltzman +18 more · 2023 · bioRxiv : the preprint server for biology · Cold Spring Harbor Laboratory · added 2026-04-24
Protein synthesis is frequently dysregulated in cancer and selective inhibition of mRNA translation represents an attractive cancer therapy. Here, we show that therapeutically targeting the RNA helica Show more
Protein synthesis is frequently dysregulated in cancer and selective inhibition of mRNA translation represents an attractive cancer therapy. Here, we show that therapeutically targeting the RNA helicase eIF4A by Zotatifin, the first-in-class eIF4A inhibitor, exerts pleiotropic effects on both tumor cells and the tumor immune microenvironment in a diverse cohort of syngeneic triple-negative breast cancer (TNBC) mouse models. Zotatifin not only suppresses tumor cell proliferation but also directly repolarizes macrophages towards an M1-like phenotype and inhibits neutrophil infiltration, which sensitizes tumors to immune checkpoint blockade. Mechanistic studies revealed that Zotatifin reprograms the tumor translational landscape, inhibits the translation of Show less
📄 PDF DOI: 10.1101/2023.09.28.559973
FGFR1
Jieyan Zhou, Ming Zhang, Mingjun Zhang +4 more · 2023 · Experimental biology and medicine (Maywood, N.J.) · SAGE Publications · added 2026-04-24
MicroRNAs (miRNAs) have been identified as crucial modulators of gene expression and to play a role in palatogenesis. The aim of this study was to explore the potential role and regulatory mechanisms Show more
MicroRNAs (miRNAs) have been identified as crucial modulators of gene expression and to play a role in palatogenesis. The aim of this study was to explore the potential role and regulatory mechanisms of miRNAs during palatogenesis. RNA-sequencing was performed to compare the RNA expression profiles of mouse embryonic palatal shelf (MEPS) tissue between an all-trans retinoic acid (ATRA)-induced group and control group, followed by reverse transcription-quantitative polymerase chain reaction for validation, demonstrating upregulated expression of miRNA-470-5p and downregulated expression of Show less
no PDF DOI: 10.1177/15353702231182215
FGFR1
Jiwei Mao, Wanli Ye, Dongping Wu +4 more · 2023 · Frontiers in pharmacology · Frontiers · added 2026-04-24
For patients with locally unresectable recurrent nasopharyngeal carcinoma who relapsed after 2 years of radiotherapy, re-radiotherapy is also the preferred treatment. However, for patients relapsed wi Show more
For patients with locally unresectable recurrent nasopharyngeal carcinoma who relapsed after 2 years of radiotherapy, re-radiotherapy is also the preferred treatment. However, for patients relapsed within 2 years, the use of re-radiotherapy would be greatly limited by its adverse effects. Consequently, finding a new strategy to prolong the time of re-radiotherapy for locally recurrent nasopharyngeal carcinoma is very necessary to reduce the related side effects and improve the curative effect. Anlotinib is an orally available small molecule multi-target tyrosine kinase inhibitor that primarily inhibits VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret. However, whether recurrent nasopharyngeal carcinoma patients can be treated with anlotinib combined with ticeorgio (also called S-1) remains unknown. Herein, we report a nasopharyngeal carcinoma patient with local recurrence after radical radiotherapy who benefited from combination treatment of anlotinib with ticeorgio. Show less
📄 PDF DOI: 10.3389/fphar.2023.1166809
FGFR1
Xiaoding Liu, Xianglin Yin, Dongmei Li +8 more · 2023 · Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · Elsevier · added 2026-04-24
Phosphaturic mesenchymal tumors (PMTs) are rare neoplasms of soft tissue or bone. Although previous studies revealed that approximately 50% of PMTs harbor FN1::FGFR1 fusions, the molecular mechanisms Show more
Phosphaturic mesenchymal tumors (PMTs) are rare neoplasms of soft tissue or bone. Although previous studies revealed that approximately 50% of PMTs harbor FN1::FGFR1 fusions, the molecular mechanisms in the remaining cases are largely unknown. In this study, fusion genes were investigated using RNA-based next-generation sequencing in 76 retrospectively collected PMTs. Novel fusions were validated with Sanger sequencing and fluorescence in situ hybridization. Fusion genes were detected in 52/76 (68.4%) PMTs, and 43/76 (56.6%) harbored FN1::FGFR1 fusions. Fusion transcripts and breakpoints of the FN1::FGFR1 fusions were diverse. The most common fusion transcript was between exon 20 of FN1 and exon 9 of FGFR1 (7/43, 16.3%). The most upstream breakpoint of the FN1 gene was located at the 3' end of exon 12, and the most downstream breakpoint of the FGFR1 gene was at the 5' end of exon 9, suggesting the inessential nature of the third fibronectin-type domain of FN1 and the necessity of the transmembrane domain of FGFR1 in the FN1::FGFR1 fusion protein, respectively. Moreover, the reciprocal FGFR1::FN1 fusions, which had not been identified in previous studies, were detected in 18.6% (8/43) of FN1::FGFR1 fusion-positive PMTs. Novel fusions were identified in 6/76 (7.9%) FN1::FGFR1 fusion-negative PMTs, including 2 involving FGFR: FGFR1::USP33 (1/76, 1.3%) and FGFR1::TLN1 (1/76, 1.3%). Other novel fusions identified were the PDGFRA::USP35 (1/76, 1.3%), SPTBN1::YWHAQ (1/76, 1.3%), GTF2I::RALGPS1 (1/76, 1.3%), and LTBP1::VWA8 (1/76, 1.3%) fusions. In addition to these novel fusions, FN1::FGFR2 (1/76, 1.3%), NIPBL::BEND2 (1/76, 1.3%), and KIAA1549::BRAF fusions (1/76, 1.3%) were also identified in FN1::FGFR1-negative cases arising from the thigh, ilium, and acetabulum, respectively. The frequency of oncogenic fusions was significantly higher (P = .012) in tumors derived from extremities (29/35, 82.9%) compared with other locations (23/41, 56.1%). No significant correlation was identified between fusions and recurrence (P = .786). In conclusion, we report fusion transcripts and breakpoints of FN1::FGFR1 in PMTs in detail, providing insights into fusion protein functions. We also revealed that a considerable proportion of PMTs without FN1::FGFR1 fusion carried novel fusions, providing further insight into the genetic basis of PMTs. Show less
no PDF DOI: 10.1016/j.modpat.2023.100266
FGFR1